
Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Research analysts at Zacks Research decreased their FY2026 EPS estimates for Gilead Sciences in a research report issued on Thursday, November 12th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($0.86) per share for the year, down from their previous estimate of ($0.65). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $1.31 EPS, Q4 2027 earnings at $2.58 EPS and Q1 2028 earnings at $2.16 EPS.
Several other brokerages also recently issued reports on GILD. Wells Fargo & Company lifted their price objective on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Bank of America increased their target price on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research note on Friday, October 30th. Cantor Fitzgerald lifted their price target on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.63.
Read Our Latest Research Report on GILD
Gilead Sciences Price Performance
NASDAQ GILD opened at $167.58 on Monday. The stock’s 50 day simple moving average is $155.43 and its 200 day simple moving average is $141.94. Gilead Sciences has a one year low of $116.88 and a one year high of $176.58. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.47 earnings per share.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is -103.80%.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, EVP Wettan Keeley M. Cain sold 3,399 shares of the stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the transaction, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 211,709 shares of company stock worth $35,234,427 over the last ninety days. 0.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Gilead Sciences
Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Gilead Sciences in the second quarter worth about $15,393,785,000. State Street Corp lifted its position in Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi lifted its position in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $1,316,606,000. Finally, Deutsche Bank AG bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Latest Gilead Sciences News
Here’s some of the latest news about GILD:
- Positive Sentiment: Gilead signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease post-exposure prevention in 127 primarily low- and lower-middle-income countries. This may broaden access and strengthen Gilead’s profile, though the drug is not yet approved. Reuters article
- Neutral Sentiment: Barclays raised its price target from $145 to $160 but kept an “equal weight” rating. The higher target is an improvement, although it remains below the stock’s cited recent price, signaling a measured view of further upside. Barclays ratings
- Negative Sentiment: Zacks Research made mixed earnings revisions: it lowered its Q4 2026 EPS estimate to $1.31 from $2.14 and its FY2026 estimate to a loss of $0.86 per share from a loss of $0.65, while slightly raising its Q1 2028 forecast. The near-term cuts may weigh on sentiment. Zacks Research forecast article
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Read More
- Five stocks we like better than Gilead Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
